OncoCyte - OCX Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares.
View OCX analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month price objectives for OncoCyte's stock. Their OCX share price forecasts range from $0.50 to $3.00. On average, they anticipate the company's stock price to reach $1.35 in the next twelve months. This suggests a possible upside of 450.6% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.

OncoCyte's stock was trading at $0.3209 at the beginning of 2023. Since then, OCX stock has decreased by 23.6% and is now trading at $0.2452.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our OCX earnings forecast.

OncoCyte will be holding an earnings conference call on Wednesday, March 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

OncoCyte Co. (NASDAQ:OCX) issued its earnings results on Tuesday, November, 9th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The company earned $0.98 million during the quarter, compared to the consensus estimate of $3.20 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 54.99%.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AWM Investment Company Inc. (6.11%), Defender Capital LLC. (1.92%), Millennium Management LLC (0.47%), Schonfeld Strategic Advisors LLC (0.36%), Penbrook Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends.

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCX stock can currently be purchased for approximately $0.25.

OncoCyte (NASDAQ:OCX) has a market capitalization of $29.09 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.